Imagine cells as tiny factories that release small bubbles called exosomes to heal the body. Usually, collecting these bubbles is slow and expensive, like trying to catch raindrops with a spoon. This technology uses a special physical trigger to shake the cells just right, making them release ten times more bubbles in a fraction of the time.
Current exosome production methods have low yields and are not scalable or GMP-compliant. This creates a bottleneck that prevents promising regenerative therapies for stroke and heart failure from reaching the clinic.
A patented, GMP-compliant EV bioproduction platform scaled to 6L using a physically triggered production technology.
If you are a biotech company dealing with low yields of therapeutic vesicles — this project developed a GMP-compliant production process that produces 10 times more EVs in 1/10th of the time. This allows for faster transition from lab to clinical trials.
If you are a CDMO dealing with the lack of scalable EV production methods — this project developed a platform scaled up to 6L. This enables the production of quantities needed for phase I trials, placing the provider 2 years ahead of competitors.
If you are a research center dealing with the high cost of EV-based therapies for stroke or heart failure — this project developed a cost-effective, standardized production platform. It ensures a steady supply of GMP-compliant materials for patient administration.
The project developed a cost-effective production process that is designed to be more affordable than current methods by increasing yield and reducing time.
The platform has been successfully scaled up to 6L, which meets the quantities required for phase I clinical trials.
Yes, the production process is based on a patented technology and over 10 years of academic research.
The objective of the project was to develop a GMP-compliant bioproduction process to facilitate clinical development.
Based on the project objective, the 6L scale-up places the technology at least 2 years ahead of known competitors.
The project is led by a single French SME, EVERZOM, with a 100% industry ratio. This lean structure indicates a highly focused commercial drive, leveraging 10 years of prior academic research to move directly into industrial scaling without the overhead of a large academic consortium.
Contact EVERZOM in France for licensing or partnership opportunities regarding EV bioproduction.
Contact us to explore partnership opportunities with EVERZOM for GMP-compliant EV manufacturing.
